BJL
RCKT icon

Brighton Jones LLC’s Rocket Pharmaceuticals RCKT Stock Holding History

Brighton Jones LLC’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Buy
32,987
+8,221
+33% +$27.3K ﹤0.01% 1303
2026
Q1 		$88.7K Buy
+24,766
New +$98.4K ﹤0.01% 1132

Other funds holding RCKT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Brighton Jones LLC's RCKT Position: Q2 2026 in Review

Brighton Jones LLC increased its Rocket Pharmaceuticals (RCKT) stake by 33% in Q2 2026, buying an estimated $27.3K and bringing the position to 32,987 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #1303.

Brighton Jones LLC first reported a position in RCKT in Q1 2026 and has held it in 2 quarters since. 74 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Brighton Jones LLC held 32,987 shares of Rocket Pharmaceuticals worth $113K as of Q2 2026.
  • Brighton Jones LLC bought 8,221 Rocket Pharmaceuticals shares in Q2 2026, an estimated $27.3K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1303 holding.
  • Brighton Jones LLC first reported a position in Rocket Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 74 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.